EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial

Siegfried Kasper, Hans-Peter Volz, Hans-Jürgen Möller, Sandra Schläfke, Stephan Klement, Ion-George Anghelescu, Erich Seifritz

European Archives of Psychiatry and Clinical Neuroscience · 2025

DOI: 10.1007/s00406-024-01783-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, 2025. Verfasst von Siegfried Kasper und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Vienna, Austria. siegfried.kasper@meduniwien.ac.at. Hauptthemen laut MEDLINE: Major Depressive Disorder, Sertraline, Oils, Volatile, Plant Oils. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dr. Willmar Schwabe, Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anxiety and depressive disorders have overlapping symptoms and share common neurobiological pathways. Antidepressant drugs have been demonstrated to be efficacious in anxiety as well. Vice versa, it may also be promising to investigate the efficacy of anxiolytic drugs such as silexan in major depressive disorder (MDD). Patients with a mild or moderate, single or recurrent episode of MDD and a total score of 19–34 points on the Montgomery Åsberg Depression Rating Scale (MADRS) were randomized to receive 1 × 80 mg/d silexan, 1 × 50 mg/d sertraline, or placebo double-blind, double-dummy for 56 days. The primary outcome measure was the MADRS total score change between baseline and treatment end. Treatment groups were compared using a treatment policy estimand. 498 subjects (silexan 170, sertraline 171, placebo 157) were treated and analyzed. After 8 weeks, silexan and sertraline were superior to placebo for MADRS total score reduction, with absolute differences to placebo of 2.17 (95% confidence interval: 0.58; 3.76) points and 2.59 (1.02; 4.17) points, respectively ( p < 0.01). Moreover, silexan was superior to placebo for alleviation of functional impairment according to the Sheehan Disability Scale with a difference of 2.40 (1.04; 3.76) points ( p < 0.001). Both treatments were well tolerated; eructation was the most frequent adverse effect of silexan. The study confirms the antidepressant efficacy of silexan in mild or moderate MDD, including significant improvements in the subjects’ functional capacity. The results for sertraline confirm the assay sensitivity of the trial. Both drugs were well tolerated. Trial registration EudraCT2020-000688–22 first entered on 12/08/2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderSertralineOils, VolatilePlant OilsAntidepressive AgentsOutcome Assessment, Health CareHumansFemaleAdultMaleMiddle AgedDouble-Blind MethodLavandulaYoung AdultAged

Stichwörter der Autor:innen

Clinical trialDepressionLavenderSilexanTreatment efficacy

Substanzen

Sertralinelavender oilOils, VolatilePlant OilsAntidepressive Agents

Autor:innen und Institutionen

  • Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Vienna, Austria. siegfried.kasper@meduniwien.ac.at.
  • Würzburg, Former Medical Director Hospital for Psychiatry, Psychotherapy and Psychosomatic Medicine Schloss Werneck, Werneck, Germany.
  • Clinic and Policlinic for Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany.
  • Department of Research and Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
  • Clinic of Psychiatry and Psychotherapy, Mental Health Institute Berlin, Berlin, Germany.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.

Förderung

  • Dr. Willmar Schwabe
  • Medical University of Vienna

Zitieren

APA

Kasper, S., Volz, H. P., Möller, H. J., Schläfke, S., Klement, S., Anghelescu, I. G., & Seifritz, E. (2025). Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01783-2

Vancouver

Kasper S, Volz HP, Möller HJ, Schläfke S, Klement S, Anghelescu IG, et al. Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial. European Archives of Psychiatry and Clinical Neuroscience. 2025. doi:10.1007/s00406-024-01783-2

BibTeX
@article{Kasper2025,
  author = {Kasper, Siegfried and Volz, Hans-Peter and Möller, Hans-Jürgen and Schläfke, Sandra and Klement, Stephan and Anghelescu, Ion-George and Seifritz, Erich},
  title = {Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial},
  journal = {European Archives of Psychiatry and Clinical Neuroscience},
  year = {2025},
  doi = {10.1007/s00406-024-01783-2}
}
Kostenlos starten →